These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 38772713)

  • 1. Comments on: Increasing Enzyme Mannose-6-Phosphate Levels but Not Miglustat Coadministration Enhances the Efficacy of Enzyme Replacement Therapy in Pompe Mice.
    Brudvig JJ; Tuske S; Castelli J; Weimer JM
    J Pharmacol Exp Ther; 2024 May; 389(3):310-312. PubMed ID: 38772713
    [No Abstract]   [Full Text] [Related]  

  • 2. Response to Comments on "Increasing Enzyme Mannose-6-Phosphate Levels but Not Miglustat Coadministration Enhances the Efficacy of Enzyme Replacement Therapy in Pompe Mice".
    George K; Anding A
    J Pharmacol Exp Ther; 2024 May; 389(3):313-314. PubMed ID: 38772716
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improved efficacy of a next-generation ERT in murine Pompe disease.
    Xu S; Lun Y; Frascella M; Garcia A; Soska R; Nair A; Ponery AS; Schilling A; Feng J; Tuske S; Valle MCD; Martina JA; Ralston E; Gotschall R; Valenzano KJ; Puertollano R; Do HV; Raben N; Khanna R
    JCI Insight; 2019 Mar; 4(5):. PubMed ID: 30843882
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 104-week efficacy and safety of cipaglucosidase alfa plus miglustat in adults with late-onset Pompe disease: a phase III open-label extension study (ATB200-07).
    Schoser B; Kishnani PS; Bratkovic D; Byrne BJ; Claeys KG; Díaz-Manera J; Laforêt P; Roberts M; Toscano A; van der Ploeg AT; Castelli J; Goldman M; Holdbrook F; Sitaraman Das S; Wasfi Y; Mozaffar T;
    J Neurol; 2024 May; 271(5):2810-2823. PubMed ID: 38418563
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design of Potent Mannose 6-Phosphate Analogues for the Functionalization of Lysosomal Enzymes To Improve the Treatment of Pompe Disease.
    El Cheikh K; Basile I; Da Silva A; Bernon C; Cérutti P; Salgues F; Perez M; Maynadier M; Gary-Bobo M; Caillaud C; Cérutti M; Garcia M; Morère A
    Angew Chem Int Ed Engl; 2016 Nov; 55(47):14774-14777. PubMed ID: 27774736
    [TBL] [Abstract][Full Text] [Related]  

  • 6. N-Butyl-l-deoxynojirimycin (l-NBDNJ): Synthesis of an Allosteric Enhancer of α-Glucosidase Activity for the Treatment of Pompe Disease.
    D'Alonzo D; De Fenza M; Porto C; Iacono R; Huebecker M; Cobucci-Ponzano B; Priestman DA; Platt F; Parenti G; Moracci M; Palumbo G; Guaragna A
    J Med Chem; 2017 Dec; 60(23):9462-9469. PubMed ID: 29112434
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficient therapy for refractory Pompe disease by mannose 6-phosphate analogue grafting on acid α-glucosidase.
    Basile I; Da Silva A; El Cheikh K; Godefroy A; Daurat M; Harmois A; Perez M; Caillaud C; Charbonné HV; Pau B; Gary-Bobo M; Morère A; Garcia M; Maynadier M
    J Control Release; 2018 Jan; 269():15-23. PubMed ID: 29108866
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The pharmacological chaperone AT2220 increases recombinant human acid α-glucosidase uptake and glycogen reduction in a mouse model of Pompe disease.
    Khanna R; Flanagan JJ; Feng J; Soska R; Frascella M; Pellegrino LJ; Lun Y; Guillen D; Lockhart DJ; Valenzano KJ
    PLoS One; 2012; 7(7):e40776. PubMed ID: 22815812
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A chaperone enhances blood α-glucosidase activity in Pompe disease patients treated with enzyme replacement therapy.
    Parenti G; Fecarotta S; la Marca G; Rossi B; Ascione S; Donati MA; Morandi LO; Ravaglia S; Pichiecchio A; Ombrone D; Sacchini M; Pasanisi MB; De Filippi P; Danesino C; Della Casa R; Romano A; Mollica C; Rosa M; Agovino T; Nusco E; Porto C; Andria G
    Mol Ther; 2014 Nov; 22(11):2004-12. PubMed ID: 25052852
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibody-mediated enzyme replacement therapy targeting both lysosomal and cytoplasmic glycogen in Pompe disease.
    Yi H; Sun T; Armstrong D; Borneman S; Yang C; Austin S; Kishnani PS; Sun B
    J Mol Med (Berl); 2017 May; 95(5):513-521. PubMed ID: 28154884
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy of cipaglucosidase alfa plus miglustat versus alglucosidase alfa plus placebo in late-onset Pompe disease (PROPEL): an international, randomised, double-blind, parallel-group, phase 3 trial.
    Schoser B; Roberts M; Byrne BJ; Sitaraman S; Jiang H; Laforêt P; Toscano A; Castelli J; Díaz-Manera J; Goldman M; van der Ploeg AT; Bratkovic D; Kuchipudi S; Mozaffar T; Kishnani PS;
    Lancet Neurol; 2021 Dec; 20(12):1027-1037. PubMed ID: 34800400
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The pharmacological chaperone N-butyldeoxynojirimycin enhances enzyme replacement therapy in Pompe disease fibroblasts.
    Porto C; Cardone M; Fontana F; Rossi B; Tuzzi MR; Tarallo A; Barone MV; Andria G; Parenti G
    Mol Ther; 2009 Jun; 17(6):964-71. PubMed ID: 19293774
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Conjugation of mannose 6-phosphate-containing oligosaccharides to acid alpha-glucosidase improves the clearance of glycogen in pompe mice.
    Zhu Y; Li X; Kyazike J; Zhou Q; Thurberg BL; Raben N; Mattaliano RJ; Cheng SH
    J Biol Chem; 2004 Nov; 279(48):50336-41. PubMed ID: 15383547
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correction of oxidative stress enhances enzyme replacement therapy in Pompe disease.
    Tarallo A; Damiano C; Strollo S; Minopoli N; Indrieri A; Polishchuk E; Zappa F; Nusco E; Fecarotta S; Porto C; Coletta M; Iacono R; Moracci M; Polishchuk R; Medina DL; Imbimbo P; Monti DM; De Matteis MA; Parenti G
    EMBO Mol Med; 2021 Nov; 13(11):e14434. PubMed ID: 34606154
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cipaglucosidase Alfa: First Approval.
    Blair HA
    Drugs; 2023 Jun; 83(8):739-745. PubMed ID: 37184753
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Duvoglustat HCl Increases Systemic and Tissue Exposure of Active Acid α-Glucosidase in Pompe Patients Co-administered with Alglucosidase α.
    Kishnani P; Tarnopolsky M; Roberts M; Sivakumar K; Dasouki M; Dimachkie MM; Finanger E; Goker-Alpan O; Guter KA; Mozaffar T; Pervaiz MA; Laforet P; Levine T; Adera M; Lazauskas R; Sitaraman S; Khanna R; Benjamin E; Feng J; Flanagan JJ; Barth J; Barlow C; Lockhart DJ; Valenzano KJ; Boudes P; Johnson FK; Byrne B
    Mol Ther; 2017 May; 25(5):1199-1208. PubMed ID: 28341561
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increasing Enzyme Mannose-6-Phosphate Levels but Not Miglustat Coadministration Enhances the Efficacy of Enzyme Replacement Therapy in Pompe Mice.
    Anding A; Kinton S; Baranowski K; Brezzani A; De Busser H; Dufault MR; Finn P; Keefe K; Tetrault T; Li Y; Qiu W; Raes K; Vitse O; Zhang M; Ziegler R; Sardi SP; Hunter B; George K
    J Pharmacol Exp Ther; 2023 Nov; 387(2):188-203. PubMed ID: 37679046
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined miglustat and enzyme replacement therapy in two patients with type 1 Gaucher disease: two case reports.
    Amato D; Patterson MA
    J Med Case Rep; 2018 Jan; 12(1):19. PubMed ID: 29373994
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glycoengineered acid alpha-glucosidase with improved efficacy at correcting the metabolic aberrations and motor function deficits in a mouse model of Pompe disease.
    Zhu Y; Jiang JL; Gumlaw NK; Zhang J; Bercury SD; Ziegler RJ; Lee K; Kudo M; Canfield WM; Edmunds T; Jiang C; Mattaliano RJ; Cheng SH
    Mol Ther; 2009 Jun; 17(6):954-63. PubMed ID: 19277015
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low-frequency enzyme replacement therapy in late-onset Pompe disease.
    Lin DS; Chiang MF; Ho CS; Hsiao CD; Lin CY; Wang NL; Chuang CK; Huang YW; Chang PC; Liu HL
    Muscle Nerve; 2013 Apr; 47(4):612-3. PubMed ID: 23322609
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.